Newer approaches for the management of Cholestatic Pruritus treatment outlook

26 Mar 2021
www.globenewswire.com
Small molecular drug
Los Angeles, USA, March 25, 2021 (GLOBE NEWSWIRE) -- Newer approaches for the management of Cholestatic Pruritus treatment outlook Cholestatic Pruritus clinical trials are ongoing with novel agents that demonstrate potential efficacious options in the future. The key players such as Escient Pharmaceuticals, Cara Therapeutics, GlaxoSmithKline, CymaBay Therapeutics, Mirum Pharmaceuticals, and others are developing Cholestatic Pruritus therapies to improve treatment outlook. DelveInsight’s “Cholestatic Pruritus Pipeline Insight” report provides comprehensive insights about 6+ companies and 6+ pipeline drugs in the Cholestatic Pruritus pipeline landscapes. It comprises Cholestatic Pruritus pipeline drug profiles, including clinical and non-clinical stage products. It also includes the Cholestatic Pruritus therapeutics assessment by product type, stage, route of administration, and molecule type and further highlights the inactive Cholestatic Pruritus pipeline products. Some of the key takeaways of the Cholestatic Pruritus Pipeline Report Get an overview of pipeline landscape @ Cholestatic Pruritus Clinical Trial Analysis Cholestasis is a reduction in bile flow because of the impaired secretion by hepatocytes or due to the obstruction of bile flow through intra-or extra-hepatic bile ducts. Furthermore, Pruritus is a distressing manifestation of both intra-hepatic cholestasis and extra-hepatic biliary obstruction. Cholestatic Pruritus Pipeline Therapeutics GSK2330672 is a selective inhibitor of human IBAT and is designed to be a non-absorbable agent restricted to the gastrointestinal (GI) tract. The drug is expected to block the uptake of bile acids (BAs) in the terminal ileum, increase their excretion in the faeces and reduce the amount of BAs returning to the liver via enterohepatic circulation. Therefore, the treatment of PBC patients with oral GSK2330672 is postulated to reduce the concentrations of BAs in the systemic circulation, and in turn, improve pruritus. The company has completed the Phase II stage of clinical development, and the drug is currently conducting phase III trials. Research and Development Phase III Clinical Studies NCT04167358: In July 2020, GlaxoSmithKline initiated a trial titled “Long-term Safety and Tolerability Study of Linerixibat for the Treatment of Cholestatic Pruritus in Participants With Primary Biliary Cholangitis”. The trial is currently recruiting participants with an estimated enrollment of 75 participants and is expected to be completed by December 2024. Phase II Results:In 2020, GlaxoSmithKline announced further progression in its R&D pipeline with the data presentation of linerixibat, an investigational product for the potential treatment of Cholestatic Pruritus in patients with Primary Biliary Cholangitis (PBC). The dose of linerixibat showed significant improvements from baseline in measures of quality of life, including social and emotional domains of the disease-specific patient-reported instrument, PBC-40, in the overall population. Due to the mechanism of action of linerixibat, the most common adverse events were diarrhoea and abdominal pain. For further information, refer to the detailed report @ Cholestatic Pruritus Emerging Drugs Scope of Cholestatic Pruritus Pipeline Drug Insight Key Questions regarding Current Cholestatic Pruritus Treatment Landscape  and Emerging Therapies Answered in the Pipeline Report Table of Contents Get a customised pipeline report @ Cholestatic Pruritus Drugs Pipeline Report Related Reports DelveInsight's Cholestatic Pruritus - Market Insights, Epidemiology and Market Forecast - 2030 report provides the detailed overview of the disease and in depth understanding of historical and forecasted epidemiology. DelveInsight's Cholestatic Pruritus - Epidemiology Forecast 2030 report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology of Cholestatic Pruritus in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. DelveInsight’s Shingles- Market Insights, Epidemiology and Market Forecast - 2030 report provides an in-depth understanding of historical. DelveInsight's Schistosomiasis - Market Insights, Epidemiology and Market Forecast - 2030 report provides the detailed overview of the disease and in depth understanding of historical and forecasted epidemiology. DelveInsight's Parainfluenza Virus Infection - Market Insights, Epidemiology and Market Forecast - 2030 report provides a detailed understanding of historical and forecasted epidemiology. DelveInsight's NSCLC - Market Insights, Epidemiology and Market Forecast - 2030 report provides the detailed overview of the disease and in depth understanding of historical and forecasted epidemiology. DelveInsight's Nephrotic Syndrome (NS) Etiologies - Epidemiology Forecast 2030 report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology of Nephrotic Syndrome (NS) Etiologies in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. The Meibomian Gland Dysfunction market report provides current treatment practices, emerging drugs, Meibomian Gland Dysfunction market share of the individual therapies. DelveInsight' s Lactose Intolerance Market Insights, Epidemiology and Market Forecast 2030 report provides the detailed overview of the disease and in depth understanding of historical market and forecasted epidemiology. About DelveInsightDelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Organizations
Indications
Targets
-
Drugs
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.